JP2022535644A - 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法 - Google Patents
精神障害、行動障害、認知障害を処置するための医薬組成物及び方法 Download PDFInfo
- Publication number
- JP2022535644A JP2022535644A JP2021556914A JP2021556914A JP2022535644A JP 2022535644 A JP2022535644 A JP 2022535644A JP 2021556914 A JP2021556914 A JP 2021556914A JP 2021556914 A JP2021556914 A JP 2021556914A JP 2022535644 A JP2022535644 A JP 2022535644A
- Authority
- JP
- Japan
- Prior art keywords
- memantine
- azelastine
- pharmaceutical composition
- disease
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 21
- 230000003542 behavioural effect Effects 0.000 title claims abstract description 9
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 8
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims abstract description 47
- 229960004574 azelastine Drugs 0.000 claims abstract description 46
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 229960004640 memantine Drugs 0.000 claims abstract description 39
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims description 32
- 208000024827 Alzheimer disease Diseases 0.000 claims description 29
- 239000002552 dosage form Substances 0.000 claims description 12
- 229960004335 azelastine hydrochloride Drugs 0.000 claims description 8
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical group Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 229960000967 memantine hydrochloride Drugs 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 abstract description 30
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 9
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229930195712 glutamate Natural products 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 108091006146 Channels Proteins 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 208000015122 neurodegenerative disease Diseases 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
- 230000003492 excitotoxic effect Effects 0.000 description 5
- -1 magnesium [II] ions Chemical class 0.000 description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000027928 long-term synaptic potentiation Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 3
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000009460 calcium influx Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 231100000063 excitotoxicity Toxicity 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 231100000318 excitotoxic Toxicity 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000030451 Vascular dementia disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000004723 neuronal vulnerability Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
[001] 本発明は、実用医学の分野、すなわち、中枢神経系への様々な起源の器質的損傷の場合の精神的、行動的、認知的な障害の症状を軽減する向神経性作用を示す医薬組成物の併用に関する。
[002] アルツハイマー病(AD)は進行性の慢性神経変性疾患であり、通常はゆっくりと始まり、時間の経過とともに徐々に悪化する。アルツハイマー病は、高齢者の認知症の最も一般的な原因である。認知症とは、人の日常生活及び活動に支障をきたす程度の、認知機能(思考、記憶、及び推論)及び行動能力の喪失である。初期の段階では記憶喪失は軽度であるが、後期のADでは、個人は会話を継続し、その環境に反応する能力を失う。未処置の場合、ADは最終的に死に至る。進行の速度は様々であるが、診断後の典型的な平均余命は3~9年である。
[0011] 本発明は、2つの有効成分1つ以上の薬学的に許容される賦形剤を含む、医薬組成物を含む。この医薬組成物は、アゼラスチン又はアゼラスチンの薬学的に許容される塩である第1の有効成分と、メマンチン又はメマンチンの薬学的に許容される塩である第2の有効成分とを含む。
[0017] 本発明の発明者らは、驚くべきことに、活性剤、塩形態のアゼラスチン及び塩形態のメマンチンを含む経口剤形を有する医薬組成物が、精神障害、行動障害、認知障害に罹患している患者を処置するのに適していることを見出した。
[0020] 本明細書で使用される場合、以下の語及び句は、それらが使用される文脈が別の意味を示す場合を除いて、一般に、以下に記載される意味を有することを意図している。
[0039] 79歳、体重51キログラムの女性が後期アルツハイマー病と診断され、メマンチン(10mg)で5年間処置された。しかし、女性の記憶力及び認知能力は悪化し続けた。女性はほとんど何も覚えることができず、数語しか話せなかった。女性は最終的に日常活動及びパーソナルケアで24時間の補助を受けていた。女性は補助を伴っても10歩を超えて歩行することができなかった。この段階で、女性は、12mgのアゼラスチンHCl及び5mgのメマンチンHClを含有する特許請求された医薬組成物の液体経口形態での1日1回の処置を開始した。わずか1ヶ月半後、女性は補助を伴って歩行できた。3ヶ月後、女性は顔及び目の表情があり、数分間話すことができ、軽度の補助のみで歩行できた。処置の6ヶ月後、女性は自由に話し、歌を歌い、独立して歩行することができた。6ヶ月の処置中に、女性の体重は5キログラム増加した。
[0041] 81歳、体重55キログラムの女性が後期アルツハイマー病と診断された。女性は、パーソナルケア、食事、ウォーキングなどの日常活動で24時間体制の補助があった。女性は5語未満しか話すことができず、不規則な睡眠パターンを有していた。女性は、12mgのアゼラスチンHCl及び5mgのメマンチンHClを含有する特許請求された医薬組成物の液体経口形態で処置された。わずか1ヶ月半後、女性の24時間体制の補助は約50%削減された。3ヶ月後、女性は自分で基本的なパーソナルケア活動を行うことができ、10語を超えて話すことができた。
[0043] 77歳、体重66キログラムの男性が後期アルツハイマー病と診断された。男性は数語しか話せなかった。男性は睡眠に困難があった。男性の性格は、非論理的又は非合理的、不安又は過敏、及び攻撃的又は敵対的であると説明された。男性はほとんどの時間非協力的であった。男性は歩行に軽度の補助が必要であった。男性は24時間補助者によって監視されていた。男性は、14mgのアゼラスチンHCl及び5mgのメマンチンHClを含有する医薬組成物の錠剤で処置された。1ヶ月半後、男性の性格は、より理性的であり、敵意なく攻撃性がはるかに少ないと説明された。3ヶ月後、男性は定期的に眠ることができ、24時間体制の補助は必要でなくなった。男性は1分以上話すことができた。
[0045]Dreyer EB, Zhang D, Lipton SA. Transcriptional or translational inhibition blocks low dose NMDA-mediated cell death. Neuroreport. 1995;6(6):942-944.
[0046]Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A. 1995;92(16):7162-7166.
[0047]Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 1997;37(24):3483-3493.
[0048]Koh JY, Yang LL, Cotman CW. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 1990;533(2):315-320.
[0049]Harkany T, Abraham I, Timmerman W, et al. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci. 2000;12(8):2735-2745.
[0050]Zeevalk GD, Nicklas WJ. Evidence that the loss of the voltage-dependent Mg2+ block at the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J Neurochem. 1992;59(4):1211-1220.[0051]Lipton SA, Nicotera P. Calcium, free radicals and excitotoxins in neuronal apoptosis. Cell Calcium. 1998;23:2-3. 165-171.
[0052]Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5(2):160-170.
[0053]Chen HS, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells. J Physiol. 1997;499(Pt 1):27-49.
[0054]Chen HS, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci. 1992;12(11):4427-4436.
[0055]Bresink I, Benke TA, Collett VJ, et al. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol. 1996;119(2):195-204.
[0056]Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996;37(8):1618-1624.
[0057]Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol. 1993;33(4):403-407.
[0058]Gelosa P, Colazzo F, Tremoli E, Sironi L, Castiglioni L. Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases. Mediators Inflamm. 2017 May 10.
[0059]Alzheimer’s Disease International, “World Alzheimer Report 2010: the global economic impact of dementia.”
[0060]G. T. Grossberg, V. Pejovicc, M. L. Miller, and S. M. Graham, “Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer’s disease,” Dementia and Geriatric Cognitive Disorders, vol. 27, no. 2, pp. 164-172, 2009.
[0061]National Institute for Clinical Excellence (NICE), “Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease,” NICE Technology Appraisal Guidance 217, National Institute for Clinical Excellence, London, UK, 2011,
[0062]Institute for Quality and Efficiency in Health Care (IQWiG) and Federal Joint Committee, “Responder analyses on memantine in Alzheimer’s disease,” Executive Summary of Rapid Report A 10-06, Institute for Quality and Efficiency in Healthcare (IQWiG), 2011.
[0063]B. Winblad, R. W. Jones, Y. Wirth, A. Stoeffler, and H. J. Moebius, “Memantine in moderate-to-severe Alzheimer’s disease: a meta-analysis of randomised clinical trials,” Dementia and Geriatric Cognitive Disorders, vol. 24, no. 1, pp. 20-27, 2007.
[0064]S. J. Thomas and G. T. Grossberg, “Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias,” Clinical Interventions in Aging, vol. 4, pp. 367-377, 2009.
[0065]R. S. Doody, J. K. Dunn, C. M. Clark et al., “Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease,” Dementia and Geriatric Cognitive Disorders, vol. 12, no. 4, pp. 295-300, 2001.
[0066]A. Clegg, J. Bryant, T. Nicholson et al., “Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: a rapid and systematic review,” Health Technology Assessment, vol. 5, no. 1, pp. 1-137, 2001.
[0067]R. A. Hansen, G. Gartlehner, A. P. Webb, L. C. Morgan, C. G. Moore, and D. E. Jonas, “Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis,” Clinical Interventions in Aging, vol. 3, no. 2, pp. 211-225, 2008.
[0068]D. D. Christensen, “Higher-dose (23 mg/dayay) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer’s disease,” Postgraduate Medicine, vol. 124, no. 6, pp. 110-116, 2012.
[0069]J. L. Cummings, D. Geldmacher, M. Farlow, M. Sabbagh, D. Christensen, and P. Betz, “High-dose donepezil (23mg/day) for the treatment of moderate and severe Alzheimer’s disease: drug profile and clinical guidelines,” CNS Neuroscience & Therapeutics, vol. 19, no. 5, pp. 294-301, 2013.
[0070]S. Ferris, J. Cummings, D. Christensen et al., “Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate-to-severe Alzheimer’s disease: evaluating the impact of baseline severity,” Alzheimer’s Research & Therapy, vol. 5, no. 1, article 12, 2013.
[0071]A. Atri, J. L. Molinuevo, O. Lemming, Y. Wirth, I. Pulte, and D. Wilkinson, “Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy,” Alzheimer’s Research & Therapy, vol. 5, no. 1, article 6, 2013.
[0072]S. Gauthier and J. L. Molinuevo, “Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease,” Alzheimer’s & Dementia, vol. 9, no. 3, pp. 326-331, 2013.
[0073]G. Wells, B. Shea, D. O’Connell et al., The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Metaanalysis, Ottawa Hospital Research Institute, Ottawa, Canada, 2011.
[0074]C. Fox, M. Crugel, I. Maidment et al., “Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial,” PLoS ONE, vol. 7, no. 5, Article ID e35185, 2012.
[0075]H. Foerstl, S. S. Stamouli, W. Janetzky, A. Galanopoulos, C. Karageorgiou, and M. Tzanakaki, “Memantine in everyday clinical practice: a comparison of studies in Germany and Greece,” Dementia and Geriatric Cognitive Disorders, vol. 32, no. 4, pp. 267-272, 2011.
[0076]N. Herrmann, J. Cappell, G. M. Eryavec, and K. L. Lancoett, “Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer’s disease: an open-label pilot study,” CNS Drugs, vol. 25, no. 5, pp. 425-433, 2011.
[0077]J. B. Schulz, M. Rainer, H. Kluenemann et al., “Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer’s disease: results of a 16-week open-label trial,” Journal of Alzheimer’s Disease, vol. 25, no. 3, pp. 463-475, 2011.
[0078]M. Rainer, A. Wuschitz, C. Jagsch, C. Erb, J.-J. Chirikdjian, and H. A. M. Mucke, “Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study,” Journal of Neural Transmission, vol. 118, no. 8, pp. 1255-1259, 2011.
[0079]G. K. Wilcock, C. G. Ballard, J. A. Cooper, and H. Loft, “Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies,” Journal of Clinical Psychiatry, vol. 69, no. 3, pp. 341-348, 2008.
[0080]M. M. Carrasco, L. Agueera, P. Gil, A. Morinigo, and T. Leon, “Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 25, no. 4, pp. 333-340, 2011.
[0081]M. R. Farlow, S. Salloway, P. N. Tariot et al., “Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study,” Clinical Therapeutics, vol. 32, no. 7, pp. 1234-1251, 2010.
[0082]M. Farlow, F. Veloso, M. Moline et al., “Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease,” BMC Neurology, vol. 11, article 57, 2011.
[0083]E. Schwam and Y. Xu, “Cognition and function in Alzheimer’s disease: Identifying the transitions from moderate to severe disease,” Dementia and Geriatric Cognitive Disorders, vol. 29, no. 4, pp. 309-316, 2010.
[0084]A. Homma, Y. Imai, H. Tago et al., “Donepezil treatment of patients with severe Alzheimer’s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial,” Dementia and Geriatric Cognitive Disorders, vol. 25, no. 5, pp. 399-407, 2008.
[0085]S. E. Black, R. Doody, H. Li et al., “Donepezil preserves cognition and global function in patients with severe Alzheimer disease,” Neurology, vol. 69, no. 5, pp. 459-469, 2007.
[0086]R. Howard, R. McShane, J. Lindesay et al., “Donepezil and memantine for moderate-to-severe Alzheimer’s disease,” The New England Journal of Medicine, vol. 366, no. 10, pp. 893-903, 2012.
[0087]R. S. Doody, D. S. Geldmacher, M. R. Farlow, Y. Sun, M. Moline, and J. Mackell, “Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer’s disease: a subgroup analysis in patients already taking or not taking concomitant memantine,” Dementia and Geriatric Cognitive Disorders, vol. 33, no. 2-3, pp. 164-173, 2012.
[0088]M. R. Farlow, M. L. Miller, and V. Pejovic, “Treatment options in Alzheimer’s disease: maximizing benefit, managing expectations,” Dementia and Geriatric Cognitive Disorders, vol. 25, no. 5, pp. 408-422, 2008.
[0089]A. K. Wallin, N. Andreasen, S. Eriksson et al., “Donepezil in Alzheimer’s disease: what to expect after 3 years of treatment in a routine clinical setting,” Dementia and Geriatric Cognitive Disorders, vol. 23, no. 3, pp. 150-160, 2007.
[0090]S. D. Rountree, W. Chan, V. N. Pavlik, E. J. Darby, S. Siddiqui, and R. S. Doody, “Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease,” Alzheimer’s Research & Therapy, vol. 1, no. 2, article 7, 2009.
[0091]D. Galasko, F. Schmitt, R. Thomas, S. Jin, D. Bennett, and S. Ferris, “Detailed assessment of activities of daily living in moderate to severe Alzheimer’s disease,” Journal of the International Neuropsychological Society, vol. 11, no. 4, pp. 446-453, 2005.
[0092]B. Winblad and N. Poritis, “Memantine in severe dementia: results of the MBest study (benefit and efficacy in severely demented patients during treatment with memantine),” International Journal of Geriatric Psychiatry, vol. 14, no. 2, pp. 135-146, 1999.
[0093]D. Wilkinson and H. F. Andersen, “Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease,” Dementia and Geriatric Cognitive Disorders, vol. 24, no. 2, pp. 138-145, 2007.
[0094]D. Wilkinson, R. Schindler, E. Schwam et al., “Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer’s disease,” Dementia and Geriatric Cognitive Disorders, vol. 28, no. 3, pp. 244-251, 2009.
[0095]R. S. Doody, P. N. Tariot, E. Pfeiffer, J. T. Olin, and S. M. Graham, “Meta-analysis of six-month memantine trials in Alzheimer’s disease,” Alzheimer’s and Dementia, vol. 3, no. 1, pp. 7-17, 2007.
[0096]F. A. Schmitt, C. H. van Dyck, C. H. Wichems, and J. T. Olin, “Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis,” Alzheimer Disease and Associated Disorders, vol. 20, no. 4, pp. 255-262, 2006.
[0097]O. L. Lopez, J. T. Becker, A. S. Wahed et al., “Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 6, pp. 600-607, 2009.
[0098]M. Bond, G. Rogers, J. Peters et al., “The effectiveness and cost effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease: a systematic review and economic model,” NIHR HTA Programme Project Number 09/87/01, National Institute for Clinical Excellence, London, UK, 2010.
[0099]L. E. Farrimond, E. Roberts, and R. McShane, “Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review,” BMJ Open, vol. 2, no. 3, 2012.
[00100]A. Atri, L. W. Shaughnessy, J. J. Locascio, and J. H. Growdon, “Long-term course and effectiveness of combination therapy in Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 22, no. 3, pp. 209-221, 2008.
[00101]A. Atri, S. D. Rountree, O. L. Lopez, and R. S. Doody, “Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer’s disease: comparison of efficacy and effectiveness studies,” Neurodegenerative Diseases, vol. 10, no. 1-4, pp. 170-174, 2012.
[00102]C. W. Zhu and M. Sano, “Economic considerations in the management of Alzheimer’s disease,” Clinical interventions in aging, vol. 1, no. 2, pp. 143-154, 2006.
[00103]Epstein AB, van Hoven PT, Kaufman A, Carr WW. Management of allergic conjunctivitis: An evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clin Ophthalmol. 2009;3:329-336.
[00104]Bielory L, Bielory B. Ocular allergy: An allergist’s perspective. Aug 16, 2010.
[00105]Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008;14 Suppl 3:S102-S106.
[00106]Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs. 2005; 65:215-218.
[00107]Bielory L, Buddiga P, Bigelsen S. Ocular allergy treatment comparisons: Azelastine and olopatadine. Curr Allergy Asthma Rep. 2004;4:320-325.
[00108]Baudouin C. Detrimental effect of preservative in eye drops: Implications for the treatment of glaucoma. Acta Ophthalmologica. 2008;86:716-726.
[00109]Lee JS, Lee JE, Kim N, Oum BS. Comparison of the conjunctival toxicity of topical ocular antiallergic agents. J Ocul Pharmacol Ther. 2008;24:557-562.
[00110]Lambiase A, Micera A, Bonini S. Multiple action agents and the eye: Do they really stabilize mast cells? Curr Opin Allergy Clin Immunol. 2009;9:454-465.
[00111]Casale T. The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites. J Allergy Clin Immunol. 1989;83:771-776.
[00112]Hazama H, Nakajima T, Hisada T, Hamada E, Omata M, Kurachi Y. Effects of azelastine on membrane currents in tracheal smooth muscle cells isolated from the guinea-pig. Eur J Pharmacol. 1994;259: 143-150.
[00113]Perhach JL, Connell JT, Kemp JP. Treatment of upper and lower airway disease with azelastine. N Engl Reg Allergy Proc. 1987;8:121-124.
[00114]Szelenyi I, Achterrath-Tuckermann U, Schmidt J, Minker E, Paegelow I, Werner H. Azelastine: A multifaceted drug for asthma therapy. Agents Actions Suppl. 1991;34:295-311.
[00115]Galatowicz G, Ajayi Y, Stern ME, Calder VL. Ocular antiallergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. Clin Exp Allergy. 2007;37:1648-1656.
[00116]Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity. J Allergy Clin Immunol. 1996;98(6 Pt 1):1088-1096.
[00117]Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonist. Clin Pharmacokinet. 1999;36:329-352.
[00118]Loyd Allen, Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems, Tenth (2013)
[00119]Sarfaraz K. Niazi, Handbook of Pharmaceutical Manufacturing Formulations Volumes 1-6.
Claims (18)
- アゼラスチン又はアゼラスチンの薬学的に許容される塩;
メマンチン又はメマンチンの薬学的に許容される塩;及び
1つ以上の薬学的に許容される賦形剤
を含む、医薬組成物。 - 前記アゼラスチン又は前記アゼラスチンの薬学的に許容される塩が、約1mg~約50mgの範囲の量で前記医薬組成物中に存在する、請求項1に記載の医薬組成物。
- 前記メマンチン又は前記メマンチンの薬学的に許容される塩が、約1mg~約70mgの範囲の量で前記医薬組成物中に存在する、請求項1に記載の医薬組成物。
- 前記アゼラスチン又は前記アゼラスチンの薬学的に許容される塩が、約1mg~約50mgの範囲の量で前記医薬組成物中に存在し;且つ
前記メマンチン又は前記メマンチンの薬学的に許容される塩が、約1mg~約70mgの範囲の量で前記医薬組成物中に存在する、
請求項1に記載の医薬組成物。 - 前記アゼラスチンの薬学的に許容される塩が、アゼラスチン塩酸塩である、請求項2に記載の医薬組成物。
- 前記メマンチンの薬学的に許容される塩が、メマンチン塩酸塩である、請求項3に記載の医薬組成物。
- 前記アゼラスチン塩酸塩が、約2mg~約20mgの範囲の量で存在する、請求項5に記載の医薬組成物。
- 前記アゼラスチン塩酸塩が、約8mg~約16mgの範囲の量で存在する、請求項5に記載の医薬組成物。
- 前記メマンチン塩酸塩が、約2mg~約20mgの範囲の量で存在する、請求項6に記載の医薬組成物。
- 前記医薬組成物が、経口医薬剤形として製剤化される、請求項1に記載の医薬組成物。
- 前記経口医薬剤形が、固体又は液体の形態である、請求項10に記載の医薬組成物。
- 精神障害、行動障害、又は認知障害に罹患している患者を処置する方法であって、
アゼラスチン又はアゼラスチンの薬学的に許容される塩;
メマンチン又はメマンチンの薬学的に許容される塩;及び
1つ以上の薬学的に許容される賦形剤
を含む、有効量の医薬組成物を投与することを含む方法。 - 前記精神障害、行動障害、又は認知障害が、アルツハイマー病、血管性認知症、パーキンソン病、ハンチントン病、又はそれらの任意の組み合わせである、請求項12に記載の方法。
- 前記精神障害、行動障害、又は認知障害が、アルツハイマー病である、請求項12に記載の方法。
- 前記医薬組成物が、経口の固体又は液体の形態で前記患者に毎日投与される、請求項14に記載の方法。
- 前記アゼラスチン又は前記アゼラスチンの薬学的に許容される塩が、約1mg~約50mgの範囲の量で前記医薬組成物中に存在する、請求項15に記載の方法。
- 前記メマンチン又は前記メマンチンの薬学的に許容される塩が、約1mg~約70mgの範囲の量で前記医薬組成物中に存在する、請求項15に記載の方法。
- 前記アゼラスチン又は前記アゼラスチンの薬学的に許容される塩が、約1mg~約50mgの範囲の量で前記医薬組成物中に存在し;且つ
前記メマンチン又は前記メマンチンの薬学的に許容される塩が、約1mg~約70mgの範囲の量で前記医薬組成物中に存在する、
請求項12に記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/027293 WO2020209872A1 (en) | 2019-04-12 | 2019-04-12 | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022535644A true JP2022535644A (ja) | 2022-08-10 |
JP7365426B2 JP7365426B2 (ja) | 2023-10-19 |
Family
ID=72751206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021556914A Active JP7365426B2 (ja) | 2019-04-12 | 2019-04-12 | 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3952840A4 (ja) |
JP (1) | JP7365426B2 (ja) |
CN (1) | CN113939276A (ja) |
AU (1) | AU2019445048A1 (ja) |
CA (1) | CA3136633A1 (ja) |
WO (1) | WO2020209872A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
CA3137393A1 (en) * | 2019-04-30 | 2020-11-05 | Jianmin Wang | A method of treating mental, behavioral, cognitive disorders |
US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019019113A (ja) * | 2017-07-11 | 2019-02-07 | キョーリンリメディオ株式会社 | メマンチン塩酸塩含有口腔内崩壊錠 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071073B2 (en) * | 2004-11-24 | 2011-12-06 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
WO2014018563A2 (en) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for the treatment of cancer |
EP3532060A4 (en) * | 2016-10-28 | 2020-08-26 | Chase Pharmaceuticals Corporation | COMBINATIONS AND USE OF MEMANTINE |
-
2019
- 2019-04-12 EP EP19924315.5A patent/EP3952840A4/en active Pending
- 2019-04-12 JP JP2021556914A patent/JP7365426B2/ja active Active
- 2019-04-12 CA CA3136633A patent/CA3136633A1/en active Pending
- 2019-04-12 WO PCT/US2019/027293 patent/WO2020209872A1/en unknown
- 2019-04-12 CN CN201980095322.XA patent/CN113939276A/zh active Pending
- 2019-04-12 AU AU2019445048A patent/AU2019445048A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019019113A (ja) * | 2017-07-11 | 2019-02-07 | キョーリンリメディオ株式会社 | メマンチン塩酸塩含有口腔内崩壊錠 |
Non-Patent Citations (1)
Title |
---|
GERIATR GERONTOL INT, vol. 8, JPN6023007352, 2008, pages 59 - 61, ISSN: 0004998603 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
Also Published As
Publication number | Publication date |
---|---|
EP3952840A4 (en) | 2022-11-23 |
CN113939276A (zh) | 2022-01-14 |
EP3952840A1 (en) | 2022-02-16 |
JP7365426B2 (ja) | 2023-10-19 |
AU2019445048A1 (en) | 2021-12-02 |
CA3136633A1 (en) | 2020-10-15 |
WO2020209872A1 (en) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7365426B2 (ja) | 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法 | |
US10946026B2 (en) | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders | |
US11116773B2 (en) | Method of treating dementia | |
US10639315B1 (en) | Pharmaceutical compositions and methods for treating Alzheimer's disease | |
US11389458B2 (en) | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease | |
JP2022536017A (ja) | 精神障害、行動障害、認知障害を処置する方法 | |
US11690849B2 (en) | Method of treating dementia | |
US10898493B2 (en) | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease | |
JP2022539944A (ja) | 精神、行動、認知障害を治療するための新規な医薬組成物及び方法 | |
KR20060117364A (ko) | 흥분 및 그 밖의 다른 행동 장애, 특히 알츠하이머 질환과연관된 것을 치료하기 위한 1-아미노사이클로헥산 유도체 | |
KR20180051561A (ko) | 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 | |
US20210069209A1 (en) | Novel pharmaceutical compositions and methods for menopause related anxiety and depression | |
US20160256449A1 (en) | H3 receptor antagonist for use in the treatment of alzheimer's disease | |
KR20120050512A (ko) | 탈수초를 갖는 환자에서 4-아미노피리딘을 사용한 지속적 치료 | |
WO2009139470A1 (ja) | 線維筋痛症治療用医薬組成物 | |
JP6084931B2 (ja) | ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン | |
AU2021383325A1 (en) | Use of pridopidine and analogs for treating rett syndrome | |
AU2021383325A9 (en) | Use of pridopidine and analogs for treating rett syndrome | |
US20130072474A1 (en) | Treatment of dementia of alzheimer's type with masitinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220411 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220411 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220610 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230224 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230522 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230721 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230808 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230908 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231006 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7365426 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |